Samuel Wilkinson on the evidence and lived experience behind esketamine therapy, and what research and clinical practice could come next

Esketamine therapy is being assessed through both evidence and real world clinical experience, with Samuel Wilkinson outlining what the current data supports and where uncertainty remains. The discussion connects trial level outcomes to practical questions clinicians face, including how patients respond, how results should be interpreted, and what factors may influence benefit or tolerability. Wilkinson also frames what should come next for esketamine, focusing on clearer standards for use, improved research design, and progress toward a more durable understanding of where the treatment fits in modern mental health care.